PURPOSE: Efforts to conclusively establish that human epidermal receptor (HER)-2 overexpression is important to androgen-dependent carcinoma of the prostate (AD-CaP) or to progression to androgen independence (AI-CaP) have failed because of variability in tissue procurement, antibodies, immunostaining procedures, and assessment methods. However, because some in vitro and animal model data correlate HER-2 overexpression with progression to androgen independence, trials of agents that target the HER-2 receptor are under way. To clarify human tumor findings, we studied HER-2 expression at the gene (DNA), mRNA, and protein levels in well-characterized CaP specimens. EXPERIMENTAL DESIGN: Fifty AD-CaP and 25 AI-CaP specimens from similar numbers of Caucasian and African Americans were immunostained for HER-2 receptor. HER-2 mRNA levels were measured using real-time fluorescence quantitative PCR in patients for whom frozen specimens were available. HER-2 amplification was evaluated using fluorescent in situ hybridization. RESULTS: HER-2 receptor immunostained in 52% of androgen-dependent and one (4%) androgen-independent tumor. HER-2 immunostaining was not related to age, race, serum prostate-specific antigen levels, or pathologic stage and Gleason grade. HER-2 overexpression was not detected in AI-CaP at the mRNA or gene level. Mean HER-2 mRNA expression was higher (P < 0.05) in AD-CaP than AI-CaP (22,080 versus 15,496 HER-2 copies). HER-2 was not amplified in any of 20 AD-CaP or 19 AI-CaP specimens. CONCLUSIONS: HER-2 protein and message overexpression and HER-2 amplification were not found in AI-CaP.
PURPOSE: Efforts to conclusively establish that humanepidermal receptor (HER)-2 overexpression is important to androgen-dependent carcinoma of the prostate (AD-CaP) or to progression to androgen independence (AI-CaP) have failed because of variability in tissue procurement, antibodies, immunostaining procedures, and assessment methods. However, because some in vitro and animal model data correlate HER-2 overexpression with progression to androgen independence, trials of agents that target the HER-2 receptor are under way. To clarify humantumor findings, we studied HER-2 expression at the gene (DNA), mRNA, and protein levels in well-characterized CaP specimens. EXPERIMENTAL DESIGN: Fifty AD-CaP and 25 AI-CaP specimens from similar numbers of Caucasian and African Americans were immunostained for HER-2 receptor. HER-2 mRNA levels were measured using real-time fluorescence quantitative PCR in patients for whom frozen specimens were available. HER-2 amplification was evaluated using fluorescent in situ hybridization. RESULTS:HER-2 receptor immunostained in 52% of androgen-dependent and one (4%) androgen-independent tumor. HER-2 immunostaining was not related to age, race, serum prostate-specific antigen levels, or pathologic stage and Gleason grade. HER-2 overexpression was not detected in AI-CaP at the mRNA or gene level. Mean HER-2 mRNA expression was higher (P < 0.05) in AD-CaP than AI-CaP (22,080 versus 15,496 HER-2 copies). HER-2 was not amplified in any of 20 AD-CaP or 19 AI-CaP specimens. CONCLUSIONS:HER-2 protein and message overexpression and HER-2 amplification were not found in AI-CaP.
Authors: Changmeng Cai; David C Portnoy; Hongyun Wang; Xinnong Jiang; Shaoyong Chen; Steven P Balk Journal: Cancer Res Date: 2009-06-02 Impact factor: 12.701
Authors: Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin Journal: Prostate Date: 2008-12-01 Impact factor: 4.104
Authors: Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri Journal: Int J Cancer Date: 2008-12-01 Impact factor: 7.396
Authors: Shuai Gao; Huihui Ye; Sean Gerrin; Hongyun Wang; Ankur Sharma; Sen Chen; Akash Patnaik; Adam G Sowalsky; Olga Voznesensky; Wanting Han; Ziyang Yu; Elahe A Mostaghel; Peter S Nelson; Mary-Ellen Taplin; Steven P Balk; Changmeng Cai Journal: Clin Cancer Res Date: 2016-03-02 Impact factor: 12.531
Authors: Kwang Hyun Baek; Min Eui Hong; Yoon Yang Jung; Chung Hun Lee; Tae Jin Lee; Eon Sub Park; Mi Kyung Kim; Jae Hyung Yoo; Soo Whan Lee Journal: Cancer Res Treat Date: 2012-03-31 Impact factor: 4.679